No Data
No Data
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | Catalyst Pharmaceuticals : H.c. Wainwright Raises Target Price to $30 From $26
Piper Lists Eight Defensive Biotechs to Face Market Volatility
Express News | Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31
No Data